Free Newsletter
Lonza steps up for GSK and Genmab
Arzerra, the recently approved monoclonal antibody treatment for leukemia from GlaxoSmithKline and Genmab, will be manufactured by Lonza. The Swiss-based contract manufacturer performed process development and cGMP manufacturing services to support the drug's licensure.
According to Lonza, Arzerra treats chronic lymphocytic leukemia by alerting the immune system to protect B-cells, which become cancerous as a result of the disease. The drug attaches to epitope molecules on the cells' surface.
Separately, Lonza has acquired AlgoNomics NV, a Belgium-based provider of immunogenicity screening services and tools. The AlgoNomics Tripole technology platform supports Lonza's aim to incorporate quality by design at the molecular level, improving the manufacturability of protein-based drugs.
- here's the Arzerra announcement
- read the AlgoNomics release
Related Article:
Lonza Group Buys AlgoNomics
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




